BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20

Benzinga · 1d ago
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.